`Submission dated October 8, 2019
`US. Application No.: 15/808,632
`Attorney Docket No.: LUB-030
`Page 2 of 9
`
`AMENDMENTS TO THE SPECIFICATION
`
`Please amend the specification as shown:
`
`1)
`
`Please delete paragraph [0041] and replace it with the following paragraph:
`
`[0041]
`
`As used herein, the term “PRG4” is used interchangeably with the term “lubricin.”
`
`Broadly, these terms refer to any functional isolated or purified native or recombinant properly
`
`glycosylated PRG4 proteins, homologs, functional fragments, isoforms, and/or mutants thereof.
`
`A11 useful molecules comprise the sequence encoded by exon 6, or homologs or truncated
`
`versions thereof, for example, versions with fewer repeats within this central mucin-like
`
`KEPAPTT-repeat domain (SEQ ID NO: 31, together with O-linked glycosylation. A11 useful
`
`molecules also comprise at least the biological active portions of the sequences encoded by
`
`exons 1-5 and 7-12, i.e., sequences responsible for imparting to the molecule its affinity for ECM
`
`and endothelial surfaces. In certain embodiments, a preferred PRG4 protein has an average
`
`molar mass of between 50 kDa and SOOkDa, preferably between 224 to 467 kDa, comprising one
`
`or more biologically active portions of the PRG4 protein, or functional fragments, such as a
`
`lubricating fragment, or a homolog thereof. In a more preferred embodiment, a PRG4 protein
`
`comprises monomers of average molar mass of between 220 kDa to about 280 kDa.
`
`